Ongoing screening efforts (supported by novel bioinformatic approaches for ligand identification as well as an improved understanding of the mechanisms of species selectivity) may yet yield equipotent GPR35 antagonists that will enable such studies.8,35 It is hoped that future studies that assess the effects of GPR35 antagonism, along with a better understanding of the mechanisms involved in these effects, will reveal its true potential as a pharmacological target in cardiovascular disease. Here, GPR35 is linked to cardiovascular disorder.